Radon and Ovarian Cancer; FDA Rejects Drug Again; Missed Chances for Genomic Testing

High levels of residential radon were linked to a roughly 30% higher risk for ovarian cancer in postmenopausal women, an analysis of the Women’s Health Initiative showed. (JAMA Network Open)

Meanwhile, occupational exposure to asbestos-free talc was not associated with an increased risk of lung cancer, mesothelioma, or laryngeal cancer in a meta-analysis. (Journal of Thoracic Oncology)

The FDA for a second time declined to approve vusolimogene oderparepvec (RP1), Replimune’s virus-derived immunotherapy for advanced melanoma, citing insufficient evidence of benefit.

And Orca Bio said the agency delayed a decision to approve or reject its allogeneic T-cell immunotherapy for hematologic malignancies.

The FDA cleared the Onclarity at-home human papillomavirus (HPV) self-collection ‌kit for use with an approved test for cervical cancer screening, Waters Corporation announced.

A Connecticut woman who alleged her cervical cancer went undetected for years after her doctor failed to follow protocols for monitoring high-risk HPV strains was awarded $49 million by a jury. (WTNH)

Adults who remain single have a significantly higher risk of developing cancer versus those who marry, according to a large U.S. study. (Cancer Research Communications)

A low-cost assay that sequences cell-free DNA from one blood sample showed promise in detecting liver, lung, ovarian, and stomach cancers. (UCLA Health)

A study of real-world lung cancer reports found that artificial intelligence-generated summaries were more complete, while maintaining correctness with low potential harm, compared with physician summaries. (JCO: Clinical Cancer Informatics)

Most patients with advanced or metastatic cancers — particularly Black or Hispanic patients and those with low socioeconomic status — never receive tumor genomic testing, a retrospective cohort study suggested. (JAMA Network Open)

Amplia Therapeutics said recruitment was halted for a trial evaluating investigational narmafotinib for advanced pancreatic cancer due to dose-limiting toxicity events with modified FOLFIRINOX chemotherapy.

FDA lifted a partial clinical hold on a phase II study evaluating lorigerlimab — a bispecific that simultaneously targets PD-1 and CTLA-4 — in patients with gynecologic cancers, MacroGenics said.

Former Sen. Ben Sasse (R-Neb.) talked about facing death as he battles metastatic pancreatic cancer. (New York Times)

Cambodia’s king said he will undergo treatment for prostate cancer. (AP)